Steatohepatitis/Metabolic Liver Disease News

WASHINGTON — Survodutide sustained improvement in liver fat content, liver enzymes and fibrosis biomarkers in patients with metabolic dysfunction-associated steatohepatitis at 28 weeks, according to a late-breaking abstract presented here.

WASHINGTON — The risk for advanced fibrosis was similar among patients with lean and non-lean metabolic dysfunction-associated steatotic liver disease and may be associated with genetic risk, according to data at Digestive Disease Week.

The FDA has granted breakthrough therapy designation to Durect’s larsucosterol for the treatment of patients with severe alcohol-associated hepatitis, despite mixed results from previously released topline data.

WASHINGTON — Parental obesity was associated with a nearly threefold increased risk for metabolic dysfunction-associated steatotic liver disease among offspring in early adulthood, according to data presented at Digestive Disease Week.

WASHINGTON — Bariatric surgery was associated with improved clinical outcomes and more cost-effective health care resource utilization among patients with metabolic dysfunction-associated steatotic liver disease, according to data.

WASHINGTON — Glucagon-like peptide-1 receptor agonists were associated with lower risk for progression to cirrhosis and hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes.

WASHINGTON — Patients with obesity and metabolic dysfunction-associated fatty liver disease taking glucagon-like peptide-1 receptor agonists had lower risk for all-cause mortality and major cardiovascular events, according to a presenter.

Adults with type 1 diabetes who play sports have less insulin resistance and are less likely to develop metabolic dysfunction-associated steatotic liver disease, according to study findings.

An analysis of the global online conversations of more than 1,600 healthcare professionals has revealed celebration at news of the approval of the first treatment for adults with metabolic dysfunction-associated steatohepatitis.

Food insecurity was associated with lower odds of metabolic dysfunction-associated steatotic liver disease among patients with HIV, although the presence of diabetes increased the odds of fibrosis in this population, according to data.